With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
The launch is yet another first of its kind innovation in India
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
The peptide-based vaccine induces a t cell-dependent response
Subscribe To Our Newsletter & Stay Updated
